Search PubMed⌕ Search

Biomedical subjects

T Salmi

Publications and source records attributed to T Salmi.

121 records · Page 7Linked to original sources
PubMed1976

Cervical bacterial flora in women fitted with a copper-releasing intra-uterine contraceptive device (IUD).

A bacterial culture was taken from the cervix in 85 sexually active women before, and 3 and 6 months after, insertion of either a copper-releasing or an inert intra-uterine contraceptive device (IUD). Sixty had a Copper-T (TCu-200) and 25 a Lippes loop D. Although in more than a quarter of the patients the bacterial flora increased slightly in diversity and abundance after IUD insertion, there was no difference in effect between the TCu-200 and Lippes loop D.

Adult↗
PubMed1975

The effect of systematic treatment of toxaemia of pregnancy upon fetal prognosis.

Systematic therapy for pre-eclampsia including diuretics was investigated in 604 patients in whom therapy was begun immediately the first symptoms appeared and continued until delivery. The control group consisted of 368 patients with toxemia from the two previous years who received no systematic therapy but who also underwent delivery at either the Turku City Maternity Hospital or the Women's Clinic of Turku University Central Hospital. Cases of pre-eclampsia gravis were significantly reduced (2.3 as compared with 7.3%). A significant difference was seen in the percentage of premature deliveries. In the experimental group this was 4.3% and in the control group 11.2%, (p less than 0.001). There was also a significant difference in the perinatal mortality, the values being 2.3 and 4.6%, respectively (p less than 0.05). The overal premature birth rate during these two periods remained unchanged, at 5.5 and 5.7%. The difference between the overall perinatal mortality rates was also slight (1.8 and 2.2%).

Acetazolamide↗
PubMedDate not supplied

Clonidine in the treatment of menopausal symptoms.

Thirty-seven women complaining of hot flushes, sweating and other menopausal symptoms were treated with clonidine. A double-blind crossover trial with placebo controls was undertaken. The clonidine dose was 2 X 0.025 mg/24 hours-0.075 mg/24 hours, increased if necessary at intervals of two weeks. The effect of clonidine did not differ significantly from placebo effect in the treatment of the symptoms. Side effects during clonidine management were slight and no difference was seen in their incidence compared with that in the patients treated with the placebo. A definitive placebo response was perceivable in the decreasing of symptoms.

Administration, Oral↗
PubMedDate not supplied

Ovarian production of estrogens in postmenopausal women.

We investigated the possible secretory capacity of the ovaries of 79 postmenopausal women with and without endometrial carcinoma using chemical, enzymehistochemical and ultrastructural methods. The mean serum levels of estrone, estradiol and total estrogens were higher in ovarian effluent blood than the corresponding values in cubital venous blood. There was a positive correlation between the difference of total estrogens in ovarian and cubital vein sera and, on the other hand, enzymehistochemical and ultrastructural findings in ovarian tissue. No statistical differences were found in the peripheral mean values of estrone and total estrogens between the two groups. The mean level of estradiol, however, seemed to be higher and that of estriol lower in the carcinoma patients than in the control groups.

3-Hydroxysteroid Dehydrogenases↗
PubMedDate not supplied

Electroencephalographic findings during experimental human exposure to m-xylene.

Aromatic hydrocarbon solvents, used widely in industry, cause central nervous system symptoms in exposed workers. Acute effects of m-xylene were studied in nine voluntary subjects exposed experimentally to stable or varying concentrations of m-xylene at rest or while exercising. Each subject participated in four exposure and two control sessions in a single-blind fashion. The time-weighted average (TWA) m-xylene concentration was always 200 parts per million (ppm) (8.2 mumol/l) during the 4-h exposure period, complying to a TWA of 4.1 mumol/l.8 h, which is equivalent to the hygienic limit allowed in work situations. The short-term peak concentrations were 400 ppm or less. Electroencephalography was recorded at the beginning of exposure, during exposure, and after exposure was stopped. Eighteen 60-s EEG samples for each subject on each experimental day were analyzed automatically. Exercise increased theta percentage and delta power and percentage; these changes were more prominent in the control session without exposure. Exposure increased the dominant alpha frequency and alpha percentage during the early phase of exposure and also counteracted the effects of exercise. The effects of short-term m-xylene exposure on EEG were minor, and no deleterious effects were noted. Perhaps alpha activation is indicative of stimulating and excitatory effects induced by m-xylene exposure, which has been noted heretofore in the absorption phase of alcohol intake.

Adult↗
PubMedDate not supplied

Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO).

PURPOSE: To study the risk of non-B-cell acute lymphoblastic leukemia (ALL) relapse in relation to the routines of administration of oral methotrexate (MTX) and 6-mercaptopurine (6MP) and to the erythrocyte (E) levels of the intracellular cytotoxic metabolites, that is, MTX polyglutamates and 6-thioguanine nucleotides (E-MTX and E-6TGN). PATIENTS AND METHODS: E-MTX and E-6TGN levels were measured at least three times (medians, eight and nine) in 294 children with non-B-cell ALL during oral MTX and 6MP therapy. For each patient, we registered (a) the individual circadian schedule of drug administration and (b) the coadministration of food, and (c) calculated a mean (m) of all E-MTX and E-6TGN measurements and (d) the product of mE-MTX and mE-6TGN (mE-MTX*6TGN), due to their synergistic action. RESULTS: A total of 42 patients were on a morning schedule, 219 were on an evening schedule, and 33 had miscellaneous routines. A total of 149 patients took the drugs with meals, 106 took the drugs between meals, and 39 had varying routines. With a median follow-up of 78 months, ALL has recurred in 66 patients. The patients on an evening schedule had a superior outcome [probability of event-free survival (pEFS) = 0.82 +/- 0.03 vs. 0.57 +/- 0.08; p = 0.0002], whereas the coadministration of food did not significantly influence outcome. Patients with a mE-MTX*6TGN < 813 [product of median mE-MTX (4.7 nmol/mmol Hb) and mE-6TGN (173 nmol/mmol Hb)] had an inferior outcome (pEFS = 0.70 +/- 0.04 vs. 0.85 +/- 0.03; p = 0.003), even if only patients on an evening schedule were analyzed. Thus, 109 patients on the MTX/6MP evening schedule with an mE-MTX*6TGN < or = 813 (nmol/mmol Hb)2 had a pEFS of 0.89 +/- 0.03 and a probability of continuous hematopoietic remission of 0.91 +/- 0.03. CONCLUSIONS: An evening schedule should be recommended for oral MTX/6MP maintenance therapy. The value of individual dose adjustments by E-MTX and E-6TGN remains to be determined in prospective randomized trials.

Administration, Oral↗
PubMedDate not supplied

Hormonal treatments and epithelial ovarian cancer risk.

Exogenous sex hormones are widely used by women either for pregnancy prevention, as part of infertility treatment, or for treatment of menopausal symptoms. The role of these hormones in the development of ovarian cancer has been vastly explored. The protective effect of combined oral contraceptive pill is confirmed in multiple studies, but it is not clear whether this protection also covers women with a genetic predisposition to ovarian cancer. There is no conclusive evidence of infertility treatments increasing ovarian cancer risk, but infertility as such is a risk factor. Currently available data suggest that long-term users of hormone replacement therapy may have a slightly increased risk for ovarian cancer compared to women who have never used estrogen. The risk might particularly involve the endometrioid type of ovarian cancer. Most data on ovarian cancer and estrogen comes from epidemiological studies, since the normally high concentrations of estrogens in ovarian tissue and follicular fluid make direct biologic studies on the effects of exogenous estrogens on the ovarian cell difficult. This review discusses the risk of ovarian cancer associated with the use of sex steroid hormones, with special emphasis on the possible risk associated with estrogens.

Animals↗
PubMedDate not supplied

Cytolysis and karyopyknosis in postmenopausal vaginal smears as markers of endometrial cancer, diabetes and obesity. Studies based on a ten-year follow-up.

The vaginal cytology of 507 postmenopausal women was followed prospectively for ten years. Of the subjects, the 207 with cytolytic or karyopyknotic vaginal smears constituted the study group and the 300 with atrophic smears (indicating an absence of estrogenic activity) constituted the control group at the beginning of the follow-up. A woman whose initial smear was cytolytic usually had a cytolytic smear ten years later, which implies that high postmenopausal estrogenic activity is constitutional. Both at the beginning of the study and ten years later, the mean body weights were higher in the study group than in the control group. The mean karyopyknotic index and the prevalence of cytolytic smears were significantly higher among women with impaired glucose tolerance than among subjects with a normal glucose tolerance test. During the follow-up period, 3.6% of the women in the study group and 0.7% of the women in the control group developed endometrial cancer (P less than .02). The incidence of 3.6% of endometrial cancer is significantly higher than the corresponding age-specific incidence (P less than .001). We conclude that obese and/or diabetic postmenopausal women with cytolytic or markedly karyopyknotic vaginal smears exhibit a high intrinsic estrogen activity and may thus be at risk for endometrial cancer.

Diabetes Complications↗